Stocks · Healthcare · Biotechnology
Akebia Therapeutics, Inc. AKBA
$0.87 -0.69% Close, Oct 2, 2026 · NASDAQ · Market cap $232.0M
High qualityWeak trend
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Over the past year the stock returned -67.7%, behind the S&P 500 by 82.8 percentage points.
- The stock is 73% below its highest close of the past year.
- Operating margin narrowed to -6.9% from 0.4% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 47%
- Revenue growth, 3-year CAGRBottom 13%
- Revenue growth accelerationBottom 13%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 40%
- Gross marginTop 31%
- Operating marginTop 50%
- Accruals (lower is better)Top 13%
- Interest coverTop 50%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 41%
- Free-cash-flow yieldTop 3%
- EBITDA / enterprise valueBottom 34%
- Sales / enterprise valueTop 5%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 3%
- 6-month returnBottom 11%
- 1-year return vs S&P 500Bottom 3%
- Distance from 52-week highBottom 7%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 18%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 23%
- Upside to consensus price targetBottom 23%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 17%
- Maximum drawdown, 3 yearsBottom 35%
- Beta vs S&P 500 (lower is better)Top 15%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 25.7% | 7.5% | ↓ |
| Gross margin | 74.4% | 79.5% | ↑ |
| Operating margin | 0.4% | -6.9% | ↓ |
| FCF margin | -1.3% | 18.4% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 7.5% | 25.7% | ↓ | Bottom 47% |
| Gross margin | 79.5% | 74.4% | ↑ | Top 31% |
| Operating margin | -6.9% | 0.4% | ↓ | Top 50% |
| Net margin | -13.5% | -17.9% | ↑ | — |
| Free-cash-flow margin | 18.4% | -1.3% | ↑ | — |
| Return on invested capital | -7.1% | — | Top 40% | |
| Revenue growth, 3-year CAGR | -6.9% | — | Bottom 13% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -20.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 6.1%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -34.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -1.9×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.59%
- Shareholder yield
- -1.59%
- Share count change, 1 year
- -0.6%
- Share count change, 3-year CAGR
- +13.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -27.8%
- Average 2-day reaction, last 8
- -8.1%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $1.00
- Target vs current price
- +15.6%
- Analysts with a rating
- 12
- Share rating Buy or Strong Buy
- 58%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | +52.4% | -2.3% | -34.4% | -28.4% | — |
| May 7, 2026 | -200.0% | -20.3% | -20.3% | -34.4% | -11.5% |
| Feb 26, 2026 | -66.7% | +9.1% | +3.3% | +14.9% | -15.7% |
| Nov 10, 2025 | +103.3% | -18.1% | -18.1% | -20.6% | -32.4% |
| Aug 7, 2025 | +104.6% | -20.6% | -12.9% | -20.3% | -44.6% |
| May 8, 2025 | +200.0% | +6.5% | -0.4% | +50.0% | +52.8% |
| Mar 13, 2025 | -100.0% | -12.4% | +47.2% | -11.9% | +105.7% |
| Nov 7, 2024 | -100.0% | -6.5% | -4.0% | +1.0% | +8.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.02 | -$0.04 | +52.4% | $49.1M |
| May 7, 2026 | -$0.03 | -$0.01 | -200.0% | $53.5M |
| Feb 26, 2026 | -$0.05 | -$0.03 | -66.7% | $57.6M |
| Nov 10, 2025 | $0.00 | -$0.06 | +103.3% | $58.8M |
| Aug 7, 2025 | $0.00 | -$0.02 | +104.6% | $62.5M |
| May 8, 2025 | $0.03 | -$0.03 | +200.0% | $57.3M |
| Mar 13, 2025 | -$0.10 | -$0.05 | -100.0% | $46.5M |
| Nov 7, 2024 | -$0.10 | -$0.05 | -100.0% | $37.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 0.60× | — | — | Top 5% |
| Free-cash-flow yield | 17.34% | — | — | Top 3% |
| Earnings yield | -12.49% | — | — | Bottom 41% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -12.8%
- 200-day average slope (20 days)
- -5.1%
- Distance from 50-day average
- -12.1%
- Distance from 200-day average
- -29.7%
- RSI (14)
- 40.5
- Relative volume
- 1.14×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 82.2%
- Volatility vs own 5-year history
- 54th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.49
- Correlation with S&P 500
- 0.11
- Current drawdown from 1-year high
- -72.7%
- Maximum drawdown, 3 years
- -79.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 8, 2021 | Nov 17, 2022 | -95.1% | 449 days | Not yet recovered |
| Oct 16, 2020 | Oct 30, 2020 | -41.3% | 10 days | 64 days (Feb 3, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $232.0M
- EPS, diluted (TTM)
- -$0.11
- Revenue (TTM)
- $219.1M
- 52-week range
- $0.81 – $3.20
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $211.7M | $292.5M | $194.6M | $160.2M | $236.2M |
| Gross profit | $130.2M | $270.0M | $120.5M | $97.0M | $196.7M |
| Operating income | -$264.5M | -$80.8M | -$46.3M | -$50.5M | $23.5M |
| Net income | -$282.0M | -$94.2M | -$51.9M | -$69.4M | -$5.3M |
| EPS (diluted) | -$1.48 | -$0.58 | -$0.28 | -$0.33 | -$0.02 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $37.4M | $46.5M | $57.3M | $62.5M | $58.8M | $57.6M | $53.5M | $49.1M |
| Net income | -$20.0M | -$22.8M | $6.1M | $247,000 | $540,000 | -$12.2M | -$9.1M | -$8.9M |
| EPS (diluted) | -$0.10 | -$0.10 | $0.03 | $0.00 | $0.00 | -$0.05 | -$0.03 | -$0.03 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$253.0M | -$73.2M | -$23.4M | -$40.7M | $68.0M |
| Capital expenditure | -$59,000 | -$114,000 | $0 | -$33,000 | -$291,000 |
| Free cash flow | -$253.0M | -$73.3M | -$23.4M | -$40.7M | $68.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $88.9M | $7.5M | $6.8M | $41.4M | $68.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $155.5M
- Total assets
- $349.7M
- Total liabilities
- $324.6M
- Total debt
- $54.0M
- Net debt
- -$101.6M
- Shareholders’ equity
- $25.0M
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 20,504,915
- Days to cover
- 2.76
- Change vs previous report
- -10.9%
FINRA short interest, settlement date Sep 15, 2026.